Clinical Trial Update: A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma [Phase 2, Phase 3]

View source ↗

Summary

A randomized Phase 2/3 trial evaluating RP2 in combination with Nivolumab for metastatic uveal melanoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• RP2
• nivolumab (nivolumab)

Snippet

Sponsor: Replimune, Inc. | Conditions: Metastatic Uveal Melanoma | Phase 2, Phase 3 | Status: RECRUITING